EMRIS Pharma
Developing a topical, site-restricted drug-delivery approach to prevent skin toxicities caused by targeted oncology therapies. The company focuses on preclinical research, topical formulation and localized blockade of drug-receptor interactions in skin, and has filed international patent protection and published preclinical results.
Industries
Nr. of Employees
small (1-50)
EMRIS Pharma
Products
Topical formulation for prevention of oncology drug–induced skin toxicities
A first-in-class topical product concept designed to block systemic oncology drugs at the skin toxicity site, preventing local adverse effects while preserving systemic anti-cancer activity.
Topical formulation for prevention of oncology drug–induced skin toxicities
A first-in-class topical product concept designed to block systemic oncology drugs at the skin toxicity site, preventing local adverse effects while preserving systemic anti-cancer activity.
Services
Attendance and presentations at conferences and industry events to pursue collaborations and commercialization opportunities.
Attendance and presentations at conferences and industry events to pursue collaborations and commercialization opportunities.
Expertise Areas
- Topical drug delivery
- Preclinical drug development
- Dermatologic safety for oncology therapies
- Intellectual property and patenting
Key Technologies
- Topical/dermal formulation
- Localized receptor-blocking approach
- Preclinical in vivo efficacy models
- Mechanism-based prevention of drug toxicities
News & Updates
Company attendance at Bio-Europe for business and scientific engagement.
Company attendance for dermatology-focused drug development discussions.
Company attendance at the European Life Sciences CEO Forum.
Company attendance at ESMO Translational Anticancer Therapeutics conference.
Company attendance at MIXiii Health-Tech.IL for health-tech engagement.
Peer-reviewed publication reporting preclinical results for topical blockade of drug–receptor interactions to prevent EGFR inhibitor–induced skin toxicities.
Company attendance at Bio-Europe for business and scientific engagement.
Company attendance for dermatology-focused drug development discussions.
Company attendance at the European Life Sciences CEO Forum.
Company attendance at ESMO Translational Anticancer Therapeutics conference.
Company attendance at MIXiii Health-Tech.IL for health-tech engagement.
Peer-reviewed publication reporting preclinical results for topical blockade of drug–receptor interactions to prevent EGFR inhibitor–induced skin toxicities.